Table 2.
Baseline characteristics of the MAIC populations
| CELESTIAL second-line population | RESORCE population | ||
|---|---|---|---|
| Unmatched (n = 495)a | Matching-adjusted (n = 266)b | Published (n = 573) | |
| Age < 65 years, % | 53.33 | 54.97 | 54.97 |
| Female, % | 17.58 | 18.63 | 12.04 |
| Asian geographical region, % | 22.83 | 37.70 | 37.70 |
| White, % | 58.18 | 35.95 | 35.95 |
| ECOG performance status 0, % | 56.97 | 65.79 | 65.79 |
| Child–Pugh class A, % | 98.79 | 97.91 | 97.91 |
| Duration of prior sorafenib treatment, mean (months) | 7.65 | 11.63 | 11.63 |
| Extrahepatic disease, % | 76.16 | 71.90 | 71.90 |
| Macrovascular invasion, % | 29.41 | 28.62 | 28.62 |
| Etiology, % | |||
| Hepatitis B | 37.37 | 37.70 | 37.70 |
| Alcohol use | 21.52 | 25.31 | 25.31 |
| Hepatitis C | 25.10 | 20.77 | 20.77 |
| Alpha-fetoprotein > 400 ng/ml, % | 40.81 | 43.46 | 43.46 |
aIncludes patients with missing data for effect-modifying baseline characteristics
bEffective sample size; excludes patients with missing data for effect-modifying baseline characteristics
ECOG Eastern Cooperative Oncology Group